The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 31, 2024
Filed:
Oct. 12, 2018
Applicant:
Board of Regents, the University of Texas System, Austin, TX (US);
Inventors:
Gregory Lizée, Houston, TX (US);
Cassian Yee, Houston, TX (US);
Assignee:
Board of Regents, The University of Texas System, Austin, TX (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 31/675 (2006.01); A61K 31/7076 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01); C12N 15/86 (2006.01); C07K 14/74 (2006.01);
U.S. Cl.
CPC ...
A61K 31/675 (2013.01); A61K 31/7076 (2013.01); A61K 39/4611 (2023.05); A61K 39/4615 (2023.05); A61K 39/4622 (2023.05); A61K 39/4632 (2023.05); A61K 39/46449 (2023.05); C07K 14/7051 (2013.01); C12N 5/0636 (2013.01); C12N 5/0637 (2013.01); C12N 15/86 (2013.01); A61K 2239/57 (2023.05); C07K 14/70539 (2013.01);
Abstract
Provided are T cell receptors (TCR) and TCR variable regions that can selectively bind SLC45A2. The TCR may be utilized in various therapies, such as autologous cell transplantation, to treat a cancer, such as a cutaneous melanoma, uveal melanoma, a mucosal melanoma, or a metastatic melanoma. Methods for expanding a population of T cells that target SLC45A2 are also provided.